Learn about the drug Nevanac

Nevanac is made in the form of eye drops, each bottle contains 5ml, each ml contains 1mg of Nepafenac. The active ingredient Nepafenac in Nevanac 5ml is a non-steroidal anti-inflammatory drug. After instillation, Nevanac penetrates the cornea and is then converted to Amfenac by hydrolase. It is Amfenac that is a non-steroidal anti-inflammatory agent, which inhibits the enzyme cyclooxygenase (an enzyme necessary for the production of prostaglandins).

Nevanac medicine 5ml has the following indications:
Prevention and treatment of inflammation and pain after cataract surgery; Reducing the risk of macular edema after cataract surgery in diabetic patients. Several studies in rabbits showed that Nevanac 0.1% suppressed blood-retinal barrier impairment associated with inhibition of PGE2 synthesis. In experiments, the time of inhibition of prostaglandin synthesis in the iris/ciliary body and in the retina/choroid by Nevanac was 6 hours and 4 hours, respectively. At the same time, the results of clinical studies showed that Nevanac eye drops did not have a significant effect on intraocular pressure.

3.1. Dosage For adults, including the elderly using the drug:
Prophylaxis and treatment of pain and inflammation after cataract surgery: Put 1 drop of Nevanac 0.1% into the damaged conjunctival sac, 3 times/day, starting from 1 day before and lasting for the first 2 weeks after surgery. In addition, patients can add 1 drop of Nevanac before surgery from 30 to 120 minutes; Prevention of the risk of macular edema after cataract surgery in patients with diabetes: Instill 1 drop of Nevanac into the conjunctival sac in the affected eye, 3 times a day. The duration of use is from 1 day before to 60 days after the time of surgery as prescribed by the doctor. For children: The safety and effectiveness of Nevanac eye drops in children have not been established because of a lack of research data. Therefore, treatment with Nevanac 0.1% is not recommended for children.
For patients with liver failure, kidney failure: Studies on the use of Nevanac in patients with liver disease or kidney failure are not many. However, Nepafenac is primarily eliminated via biotransformation and systemic exposure is very low with ophthalmic administration. Therefore, no dose adjustment of Nevanac is required in these patients.
3.2. How to use Nevanac should only be used by eye drops. Patients should shake the vial well before use. In cases where treatment with more than one eye medication is required, the medications should be administered at least 5 minutes apart and the eye ointment should be used last.

Hypersensitivity to the active substance Nepafenac or any of the excipients of the drug Nevanac; Hypersensitivity to other non-steroidal anti-inflammatory drugs (NSAIDs); Patients with a history of asthma, urticaria or acute rhinitis associated with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.

Do not use Nevanac for infusion or oral administration. Patients should avoid sunlight during treatment with Nevanac eye drops. Non-steroidal anti-inflammatory drugs (NSAIDs) such as Nepafenac can cause keratitis, especially in sensitive people, when used for a long time, it can weaken the epithelium, thereby causing the cornea to thin, slip, ulcerate and perforate. Therefore, patients with impaired corneal epithelial function should immediately discontinue Nevanac and monitor the corneal condition closely. Topical NSAIDs such as Nevanac eye drops can slow or interfere with wound healing. Topical NSAIDs, such as Nevanac 0.1% when indicated in patients with risk factors such as repeated and/or complicated ocular surgery, corneal denervation, corneal epithelial defects, diabetes If you have diabetes, ocular surface disease, dry eye, or rheumatoid arthritis, the chance of corneal side effects is increased, which can seriously threaten vision. Therefore, Nevanac ophthalmic should be used with caution in these patients, especially with prolonged use. Nevanac eye drops contain Benzalkonium Chloride, which may cause eye irritation and discoloration of soft contact lenses. Besides, the time after cataract surgery is not recommended for patients to wear contact lenses. Therefore, patients should not wear contact lenses while using Nevanac. Acute eye infections may be overshadowed by topical anti-inflammatory agents, whereas NSAIDs are not bactericidal. Therefore, in confirmed cases of eye infection, caution should be exercised when using Nevanac in addition to antibacterial drugs. Cross-sensitization between Nepafenac and Acetylsalicylic Acid, phenylacetic acid derivatives and other NSAIDs has been reported.

The side effects of Nevanac eye drops include:
Keratitis, punctate keratitis, allergic keratitis; Corneal epithelial defects; Eyesore; Sensation of a foreign body in the eye; Scaly eyelid margin, eyelid inflammation; Corneal deposits; Discomfort in the eyeball; Conjunctival congestion; Blurred vision, sensitivity to sunlight; Eye irritation, increased eye discharge or increased tearing.

Fertility: There are no data on the effect of Nevanac on human fertility; Pregnancy: There are no adequate data on the use of Nepafenac in pregnant women. The risk to the fetus is unknown. Since systemic exposure in nonpregnant women is negligible during treatment with Nevanac 0.1%, the drug-induced risk in pregnancy is likely to be low. However, the inhibitory effect on Prostaglandin synthesis may adversely affect pregnancy, fetal development, parturition, and postnatal development. Therefore, the use of Nevanac eye drops is not recommended for women who are pregnant or of childbearing potential who are not using contraception; Lactation: Nepafenac is not known to be excreted in human milk. Animal studies have shown that this active ingredient is excreted in the milk of rats. However, the effect of the drug on the nursing infant may not be as high as the systemic exposure of the mother to Nepafenac is negligible. Therefore, women who are breastfeeding can be treated with Nevanac.